I believe the UK has relatively few orders of the Moderna vaccine whereas they are highly reliant on the Oxford one. Makes sense for the regulatory to put all r

I believe the UK has relatively few orders of the Moderna vaccine whereas they are highly reliant on the Oxford one. Makes sense for the regulatory to put all resources on Oxford once Biontech had been approved and then (I presume) look at Moderna next.